Compare Avantis International Small Cap Value ETF (AVDV) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Avantis International Small Cap Value ETF vs BIO-TECHNE Corp — how do they compare? Avantis International Small Cap Value ETF trades at $105.24, while BIO-TECHNE Corp trades at $71.23 (market cap $11.12B). The key difference: BIO-TECHNE Corp pays a 0.45% dividend while Avantis International Small Cap Value ETF pays none, and BIO-TECHNE Corp is trading nearer its 52-week high, Avantis International Small Cap Value ETF nearer its low. Which is the better fit depends on your goals.
| AVDV | TECH | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $110.40 | $71.38 |
52-Week Low | $80.02 | $43.31 |
Market Cap | — | $11.12B |
Enterprise Value | — | $11.20B |
Dividend Yield | — | 0.45% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Avantis International Small Cap Value ETF
AVDV is an actively managed ETF that targets small-cap value companies in developed markets outside the United States. It uses a systematic, rules-based process to identify firms trading at low valuations with high profitability, aiming to capture the 'size' and 'value' premiums while maintaining broad diversification.
Read more on AVDV →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
